Trending now
Tariffs Labor Costs Platform Consolidation AI Workforce Automation Data Center Load Interest Rates AI Capex IRA Incentives FDA Approval Pathway Autonomous Systems

Companies · ICLR

ICLR Reported this cycle

ICON Public Limited Company

Dublin Founded 1990 Life Science Tools & CRO

AI-generated · informational only · not investment advice · verify before relying.

Latest analysis

Updated Aug 20, 2026

ICON Achieves Platinum ESG Status; Orbis AI Platform Gains Industry Recognition

ICON released its 2025 ESG report highlighting operational modernization through AI-enabled solutions and sustainability milestones. The company's proprietary Orbis platform won AI Project of the Year at the Analytics & AI Awards 2025, signaling deepening AI deployment across clinical trial operations. In 2025, ICON supported 1,370 clinical studies involving 411,400 patients, contributing to 25 unique product approvals, while achieving Platinum Medal status on EcoVadis (87/100) and ranking in the top 1% of assessed organizations globally.

Tone: bullish

Revenue

$8.3B

ICLR 20-F · FY 2025

Employees

40,100

Revenue growth YoY

+0.8%

Founded

1990

Profile

ICLR 20-F Item 4.B · May 27, 2026

ICON plc is a global contract research organization (CRO) founded in Dublin, Ireland in 1990 that provides outsourced clinical development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. The company offers services spanning all phases of clinical development (Phases I-IV), laboratory testing, data solutions, and site and patient access. ICON operates in 55 countries and believes it is the world's largest pure-play CRO.

Read filing description ↓

ICON is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. We offer a full range of clinical, consulting and commercial services that range from clinical development strategy, planning and trial design, to full study execution, and post-market commercialization. ICON provides its services across a range of clinical outsourcing operating models including strategic partnerships, preferred provider, full-service delivery to functional service provision and stand-alone services. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process, from compound selection to Phase I-IV clinical studies. We earn revenue by providing a number of different services to our customers. These services are integral components of the clinical development process and include clinical trial management, consulting, contract staffing, data solutions and laboratory services. Our vision is to be the partner of choice by delivering industry leading solutions and best in class performance in clinical development. We believe that we are one of a select group of CROs with the expertise and capability to conduct clinical trials in the major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated full-service solution. In order to achieve this vision, we continue to invest in technology and data analytics capabilities. ICON maintains a sustained focus on research and development. We continue to enhance our portfolio of data solutions and decentralized clinical trial technology through the development of industry-leading technologies and processes to support our clients. ICON is leading the industry transformation through four key levers: transforming clinical trials, site and patient centricity, applied innovation, and seamless, integrated service delivery.

Primary products

  • clinical trial management
  • consulting
  • contract staffing
  • data solutions
  • laboratory services
  • bio-analytical services

End markets

pharmaceutical biotechnology medical device government and public health organizations

Geographies

United States Europe Rest of World

Named customers

Pharmaceutical organisations Biotechnology organisations Medical device organisations Government organisations

During the year ended December 31, 2025, revenue was earned from a wide range of customers and 24.8% of our revenues were derived from our top five customers, with no one customer individually contributing more than 10% of our revenues during the period. Our largest customer represented a strategic partnership with a large global pharmaceutical company and contributed 7.0% of revenue for the year.

Named competitors

IQVIA PAREXEL PPD clinical research services brand of Thermo Fisher Scientific Inc. Fortrea Syneos Health
“We believe that we are one of a select group of CROs with the expertise and capability to conduct clinical trials in the major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated full-service solution.” Competitive position, as stated in the filing

Revenue commentary · FY 2025

Revenue for the year ended December 31, 2025 increased by $62.4 million, or 0.8%, to $8,251.3 million, compared to $8,189.0 million (as restated) for the year ended December 31, 2024; reported in USD.

The rest of ICLR is for subscribers

Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.

SeventhBiz analysis 6 signals 12 diligence answers 3 M&A transactions SWOT